[Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].
BACKGROUND
The incidence of endocrine carcinomas is about 5.3 persons per 100,000 population. Most frequent are malignancies of the thyroid gland (about 89%).


METHODS
Because of low incidences and missing prospective studies as well as radiotherapy and chemotherapy resistance, general accepted therapy guidelines for endocrine carcinomas are still missing. Surgery and radionucleotide treatment is generally the first-line therapy. Hormonal active carcinomas can be additionally treated with special substances such as octreotide and mitotane. Chemotherapy is frequently not effective. Widely used substances are cyclophosphamide, cisplatin, doxorubicine, dacarbazine, vincristine and etoposide. This first part of the review will present medical therapies of thyroid carcinomas, adrenal carcinomas and parathyroid carcinomas. The second part in one of the next issues will focus on less frequent endocrine carcinomas of the gastrointestinal tract.
Schott
M
M
Abteilung für Endokrinologie, Heinrich-Heine-Universität Düsseldort. schottmt@uni-duesseldorf.de
Scherbaum
W A
WA
Feldkamp
J
J
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008939:Mitotane / Q000008:administration & dosage; D015282:Octreotide / Q000008:administration & dosage; D010282:Parathyroid Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D010673:Pheochromocytoma / Q000188:drug therapy* / Q000453:epidemiology; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000453:epidemiology
D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane; D015282:Octreotide